西帕依固龈液与米诺环素软膏牙周袋给药对慢性牙周炎患者的临床疗效及其对牙周指标的影响

目的:探究西帕依固龈液与米诺环素软膏对慢性牙周炎患者的临床疗效用其对牙周指标的影响。方法:选取2017年1月—2018年12月间诊治的牙周炎患者70例资料,按治疗方法的不同将其随机分为对照组患者和观察组患者,每组35例;对照组患者给予盐酸米诺环素软膏注入牙周袋治疗;观察组患者在对照组基础上加用西帕依固龈液含潄治疗,比较两组患者治疗后的总有效率差异,以及治疗前后菌斑指数(PLI)、龈沟出血指数(SBI)评份值和探诊深度(PD)有差异。结果:治疗后观察组患者的总有效率高于对照组(P<0.05),PLI、SBI评分值和PD值均小于对照组(P<0.05)。结论:采用西帕依固龈液含潄与米诺环素软膏注入牙周袋治疗慢性牙周炎患者的疗效较为确切,有效改善了慢性牙周炎牙周指标,提高患者生活质量。     

米诺环素软膏联合替硝唑对慢性牙周炎患者的临床研究

目的 探讨米诺环素软膏联合替硝唑对慢性牙周炎患者的临床疗效.方法 选择本院2013年11月至2015年6月收治的104例慢性牙周炎患者作为研究对象,所有患者随机选择1颗患牙进行研究.将所有患者随机分为对照组(米诺环素软膏治疗)52例,观察组(米诺环素软膏联合替硝唑治疗)52例,比较两组患者的临床疗效、牙龈出血指数、牙周袋深度以及龈沟液内的炎症因子水平,并监测不良反应发生情况.结果 治疗后,观察组患者的总有效率为96.16％,明显高于对照组患者,且观察组患者的牙龈出血指数(1.86±0.45)、牙周袋深度(4.15±0.71)mm、炎症因子hs-CRP (4.65±0.73)ng· ml-1及IL-10(6.76± 1.06)μg·ml-1等均较对照组患者出现了明显改善,组间差异均具有统计学意义.结论 米诺环素软膏联合替硝唑可有效改善慢性牙周炎患者的临床症状,改善炎症介质水平,而不增加不良事件的发生率,从而提高患者的生活质量,值得临床应用.     

盐酸米诺环素软膏治疗慢性牙周炎47例疗效观察

目的:探讨盐酸米诺环素软膏治疗慢性牙周炎的疗效.方法:从我院收治的慢性牙周炎患者当中抽取94例作为临床研究对象.随机分组:对照组47例(47颗患牙),采用碘甘油进行治疗;观察组47例(47颗患牙),采用盐酸米诺环素软膏进行治疗.对两组治疗效果进行对比分析.结果:观察组治疗总有效率明显高于对照组,牙周袋深度、菌斑指数、牙周附着水平明显低于对照组,具有显著差异(P<0.05).结论:盐酸米诺环素软膏治疗慢性牙周炎的临床疗效良好,值得推广.     

盐酸米诺环素软膏与碘甘油治疗慢性牙周炎的疗效及对患者系统炎症状况的影响研究

目的探讨盐酸米诺环素软膏与碘甘油对慢性牙周炎的治疗疗效以及对患者系统炎症状况的影响。方法 80例慢性牙周炎患者共94颗患牙,按入院顺序分为两组,各47颗,两组患者均经常规龈上洁治术及龈下刮治术等基础治疗,研究组采用盐酸米诺环素软膏注入牙周袋内辅助药物治疗,对照组采用同样方法注入碘甘油。治疗结束后比较两组患者治疗疗效、牙周指标及系统炎症因子水平。结果研究组患者治疗总有效率达95.7%,明显高于对照组78.7%,比较差异具有统计学意义(P<0.05);研究组牙周指标较治疗前明显改善,且优于对照组,比较差异具有统计学意义(P<0.05);研究组治疗后的系统炎症因子C反应蛋白(CRP)较治疗前及对照组明显降低(P<0.05),而白介素-6(IL-6)变化不大。结论盐酸米诺环素软膏治疗慢性牙周炎疗效显著,值得推广应用。     

盐酸米诺环素软膏辅助治疗慢性牙周炎疗效分析

目的 分析盐酸米诺环素软膏辅助治疗慢性牙周炎的临床疗效.方法 将40例患慢性牙周炎患者每人选4颗患牙,共160颗,牙周袋深度＞4 mm同时探诊出血.将这些患者完全随机分为2组,每组20例80颗患牙.实验组患牙行牙周基础治疗,并在牙周袋内置盐酸米诺环素软膏;对照组仅作牙周基础治疗.观察2组患牙的菌斑指数和牙龈指数的变化,并将牙周袋深度,牙龈出血指数(BI)的指标比较并分析.结果 盐酸米诺环素软膏配合牙周基础治疗的实验组在1周和4周时,探诊深度、出血指数低于对照组[1周时分别为(4.35±0.95)mm比(5.08±0.90)mm、(1.59±0.21)比(2.24±0.23),4周时分别为(2.65 ±0.41)mm比(4.99 ±0.55)mm、(0.40 ±0.08)比(1.54±0.22)].结论 慢性牙周炎在基础治疗上,龈下局部应用米诺环素可取得较好的疗效.     

局部应用2%米诺环素软膏治疗慢性牙周炎的有效性及安全性

目的 探讨2%盐酸米诺环素软膏局部应用治疗慢性牙周炎的疗效、安全性及给药方法.方法 将60例(118颗牙)中重度慢性牙周炎患者随机分为治疗组和对照组,两组均给予全口洁治、根面平整等基础治疗,在此基础上治疗组30例(60颗牙)给予2%盐酸米诺环素软膏于牙周炎袋内置药,对照组30例(58颗牙)给予碘甘油于牙周炎袋内置药.治疗前、治疗后4周、8周检测菌斑指数(PLI)、龈沟出血指数(SBI)和牙周袋探诊深度(PD)并比较,同时观察不良反应.结果 与治疗前比较,两组治疗后4周、8周PLI、SBI、PD均有改善(均P<0.05),治疗组改善情况优于对照组(均P<0.05).结论 盐酸米诺环素软膏于牙周炎袋内置药治疗慢性牙周炎安全、有效.     

牙痛宁滴丸联合米诺环素软膏治疗慢性牙周炎的临床研究

目的研究牙痛宁滴丸联合米诺环素软膏治疗慢性牙周炎的临床疗效。方法选取2017年10月—2019年10月在淅川县中医院治疗的60例慢性牙周炎患者(110颗患牙),将所有患者随机分为对照组和治疗组,每组各30例55颗患牙。对照组患者给予盐酸米诺环素软膏,1次/周,连续用4次。治疗组在对照组基础上口服牙痛宁滴丸,10粒/次,3次/d。两组患者治疗4周。观察两组患者临床疗效,对比两组患者治疗前后牙周指标、口腔保健自我效能量表(SESS)评分、口腔健康影响程度量表(OHIP-14)评分和视觉模拟评分法(VAS)评分、龈沟液炎性因子水平变化。结果治疗后,治疗组总有效率(96.36%)显著高于对照组(83.64%)(P0.05)。治疗后,两组患者SESS评分显著升高,OHIP-14和VAS评分均显著降低(P0.05);且治疗组SESS评分高于对照组,OHIP-14和VAS评分均低于对照组(P0.05)。治疗后,两组患者菌斑指数(PLI)、牙周袋深度(PD)、龈沟出血指数(SBI)、牙周附着水平(AL)均显著降低(P0.05),且治疗组牙周指标降低程度较大(P0.05)。治疗后,两组患者龈沟液肿瘤坏死因子-α(TNF-α)和白细胞介素-1β(IL-1β)水平均显著降低(P0.05),且治疗组龈沟液炎性因子水平降低程度较大(P0.05)。结论牙痛宁滴丸联合米诺环素软膏治疗慢性牙周炎具有较好的治疗效果,能改善牙周指标和临床症状,降低龈沟液炎性因子水平,安全性较高,值得在临床上推广应用。     

超声龈下刮治术与米诺环素软膏联合治疗牙周炎效果观察

目的：观察超声龈下刮治术后米诺环素软膏在牙周基础治疗中的临床效果。方法：选取慢性牙周炎患者80例,随机分成两组,每组40例,作超声龈下刮治术后实验组给予米诺环素软膏,放入牙周袋内,每周放药1次。对照组给予过氧化氢液局部冲洗,1月后进行对比观察。结果：实验组牙周炎症控制和症状改善情况好于对照组。各指标比较有明显差异性。结论：超声龈下刮治术配合米诺环素软膏是行之有效的牙周炎基础治疗方法。     

盐酸米诺环素软膏治疗慢性牙周炎的临床研究

目的 探讨盐酸米诺环素软膏治疗慢性牙周炎的临床疗效.方法 选取2013年8月—2014年8月遂宁市中心医院收治的80例慢性牙周炎患者共94颗患牙,随机分为对照组和治疗组,每组47颗患牙.两组患者均给予常规龈上洁治术及龈下刮治术等基础治疗.对照组患者在牙周袋内注入碘甘油.治疗组将盐酸米诺环素软膏放入患牙牙周袋内,直至溢出.两组患者每周1次,共4次.观察两组患者的临床疗效,同时比较两组牙周袋深度(PD)、菌斑指数(PLI)、牙周附着水平(AL)、龈沟出血指数(SBI)、C反应蛋白(CRP)及白介素-6(IL-6)的变化.结果 治疗后,对照组和治疗组总有效率分别为78.72%、95.74%,两组总有效率比较差异具有统计学意义(P<0.05).治疗后,两组的 PD、PLI、AL、SBI 均较同组治疗前显著降低,同组治疗前后差异有统计学意义(P<0.05),且治疗组这些观察指标的改善程度优于对照组,两组比较差异有统计学意义(P<0.05).治疗组 CRP 较治疗前显著降低,且治疗后显著低于对照组(P<0.05).结论 盐酸米诺环素软膏治疗慢性牙周炎疗效显著,能有效改善牙周炎症,同时对患者机体的系统炎症状态起到一定的缓解作用,值得推广应用.     

米诺环素软膏治疗成人牙周炎临床研究

目的 探讨米诺环素软膏治疗成人牙周炎的临床效果。方法 随机选取临床确诊为成人牙周炎的患牙80颗分为盐酸米诺环素软膏治疗组和对照组（不用药），观察治疗前后的菌斑指数（PLI），龈沟出血指数（SBI），牙周袋深度（PD），牙周附着水平（AL）．牙齿松动度（MD）的变化。结果 治疗组在用药1周和1个月后，各项指标改善程度均明显优于对照组。结论 盐酸米诺环素软膏是一种有效的牙周局部缓释药物。     

Risk assessment for coenzyme Q10 (Ubiquinone)

Coenzyme Q10 (CoQ10) widely occurs in organisms and tissues, and is produced and used as both a drug and dietary supplement. Increasing evidence of health benefits of orally administered CoQ10 are leading to daily consumption in larger amounts, and this increase justifies research and risk assessment to evaluate the safety. A large number of clinical trials have been conducted using a range of CoQ10 doses. Reports of nausea and other adverse gastrointestinal effects of CoQ10 cannot be causally related to the active ingredient because there is no dose-response relationship: the adverse effects are no more common at daily intakes of 1200 mg than at a 60 mg. Systematic evaluation of the research designs and data do not provide a basis for risk assessment and the usual safe upper level of intake (UL) derived from it unless the newer methods described as the observed safe level (OSL) or highest observed intake (HOI) are utilized. The OSL risk assessment method indicates that the evidence of safety is strong at intakes up to 1200 mg/day, and this level is identified as the OSL. Much higher levels have been tested without adverse effects and may be safe, but the data for intakes above 1200 mg/day are not sufficient for a confident conclusion of safety.     

抗瘤酮A_(10)的药效学实验研究

本文观察了不同剂量的抗瘤酮A_(10)对动物移植性肿瘤小鼠S_(1(?)0)、大鼠W_(25(?))、裸小鼠荷人乳腺癌细胞(Bca—P6)和人胃癌细胞(MGC)的抑制效应。A_(10)大剂量组(4000mg·kg~(-1))对小鼠S_(1(?)0)的抑制率为32.5％(P<0.05);对裸鼠体内的Bca—P6和MGC细胞的抑制率分别为54.4％(P<0.001和33.9％(P<0.05);2000mg·kg~(-1)剂量对W_(206)的抑制率为41.8％(P<0.05);各中、小剂量对上述瘤株均没有明显的抑制作用.体外试验结果表明,A_(10)大剂量组(终浓度为0.12mol·L~(-1))与Bca—P6细胞接触4h可达到一个对数杀伤(杀伤90％的细胞),24h可达到2个对数杀伤(杀伤99％的细胞);HL—60细胞与药液接触24h后洗去药液继续培养48h和72h,可达到一个对效杀伤,96h可达到2个对数杀伤。其余各剂量组杀伤效果不明显。     

抗瘤酮A_(10)的合成

以苯乙酰氯和L-谷氨酰胺为起始原料,经缩合和环合两步合成抗癌新药抗瘤酮A_(10),总收率40%。     

辅酶Q_(10)高产酵母菌SY-3发酵工艺的研究

目的为了获得比较高的辅酶Q10产量,以一株酵母菌SY-3作为辅酶Q10的生产菌,研究不同的发酵条件对辅酶Q10产量的影响。方法用皂化法提取,用高效液相检测。结果与结论蔗糖是较好的碳源,蛋白胨是较好的氮源,通过均匀设计初步确定的发酵培养基为:蔗糖4.2%,蛋白胨2.8%,KH2PO40.13%。接种量2%,500mL三角瓶中装液量40mL,pH值4.0,温度26℃,转速240 r/m in,在此发酵条件下,发酵液中菌体生长量达到10g/100mL,辅酶Q10产量达到84.6mg/L。     

溶质运载蛋白16A家族成员10(SLC16A10)对胶质瘤干细胞增殖及自我更新能力的影响

目的 探索溶质运载蛋白16A家族成员10(SLC16A10)在胶质瘤干细胞(GSC)中的功能,为针对GSC的脑胶质瘤治疗提供新的潜在靶点.方法 387GSC培养于含10％胎牛血清的DMEM培养基中7 d,分化为387非干性肿瘤细胞(387NSTC),RT-qPCR检测387GSC和387NSTC中SLC16A10、性别...     

Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer

Summary Thirty-one patients with stage IIIB or IV non-small cell lung cancer (NSCLC) were treated with intravenous 10-EdAM on a weekly basis. The starting dose was 80 mg/m², with subsequent doses adjusted depending on evidence of toxicity. There were 20 men and 11 women with a median age of 58 years (range, 33–75). Response was evaluated in 30 patients, 5 with evaluable but not measurable tumors and 25 with measurable indicator lesions. There were no complete remissions; 3 patients achieved partial remission. Nine patients had a minor response, 6 showed no change, and 12 had progressive disease. Median survival for all 31 patients was 43 weeks (range, 12–65&#x002B;). During the first 3-week period, the 10-EdAM dose was reduced or withheld in 19 patients (because of stomatitis in 12, SGPT elevation in 3, skin rash in 2, and granulocytopenia in 2), escalated in 11 patients, and unchanged in 1 patient. A mean of 34–88 mg/m²of 10-EdAM (median, 50) was given per week during the first 5-week period. Myelotoxicity was infrequent and there was no significant nephrotoxicity. Considering the modest side effects of this treatment and the conservative dose-modification schedule which mandated substantial dose reductions, we conclude that 10-EdAM is a promising antitumor agent for NSCLC.     

Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles

10-Hydroxycamptothecin (HCPT) is insoluble in both water and physiological acceptable organic solvents and tends to change into its carboxylate form, which shows minimal anticancer activity and several unpredictable side effects. The goal of this study is to exploit an appropriate delivery system for HCPT to improve the stability of its lactone form. Bovine serum albumin (BSA) nanoparticles entrapping HCPT were prepared by reformative emulsion-heat stabilization technique. During this process, HCPT transformed from lactone to carboxylate and finally back to lactone form successfully. A simple reversed-phased HPLC method was developed to analyze both lactone and carboxylate forms of HCPT synchronously. Mean particle size and the ratio of lactone and carboxylate forms of HCPT were evaluated to investigate the effects of the formulations and preparation conditions. It was indicated the percentage of lactone form of HCPT in resultant BSA nanoparticles could be improved over 95% through adjusting the concentration of NaOH solution and the stirring time after high-speed emulsification. This drug delivery system was also characterized by dynamic light scattering (DLS) and light microscopy. The investigations on drug loading, in vitro release and body distribution in rats after intravenous (i.v.) administration were also carried out. It was found that the obtained nanoparticles showed spherical shape with the mean particle size of around 600 nm, and drug loading content, encapsulation efficiency and yield achieved 2.21%, 57.5% and 90.5% with the optimal preparation conditions, respectively. The in vitro release behavior exhibited a sustaining release manner and was affected by the trypsin in medium. HCPT could release more than 90% within 20 h in the medium of pH 7.4 PBS containing 750 U/ml trypsin, but only 25% within 40 h in the pure pH 7.4 PBS. The results of body distribution study in rats showed the liver targeting potential of HCPT–BSA nanoparticles that 59.6%, 52.9% and 55.3% of the examined amount of lactone HCPT accumulated in livers at 1, 4 and 24 h after injection, respectively. These results suggest that the HCPT–BSA nanoparticles seem to be a stable delivery system for poorly soluble HCPT or its derivatives.     

高效液相色谱法测定辅酶Q_(10)含量的研究

应用色谱技术，建立了辅酶Q_10(CoQ_10)含量测定的高效液相色谱方法.并从多个影响保留时间的因素中选出三个水平、三个因子进行正交设计，从而确定了CoQ10。含量测定的最佳条件。本法选用碳十八硅烷为固定相，检测波长为275um，经过多批COQ10。测定，其回收率大于99．6％，RSD小于0．07％，方法简便快速、灵敏度高、特异性强，适用于该药品的含量分析检测。     

一阶导数紫外光谱法测定辅酶Q_(10)胶囊的含量

目的 :建立用一阶导数紫外光谱法快速测定辅酶Q10 胶囊含量的方法。方法 :用无水乙醇作溶剂 ,以一阶导数紫外光谱在 2 5 6～ 2 81nm峰 谷间距离D作为定量依据 ,用标准对照法计算含量。结果 :辅酶Q10 浓度在5～ 40 μg/ml之间与一阶导数紫外光谱在 2 5 6～ 2 81nm峰 谷间距离D呈良好线性关系 (r=0 .9999) ,平均回收率为 1 0 1 .1 % ,RSD为 1 .2 % (n =5 )。结论 :此法简便、准确 ,重现性好。     

酵母菌DM10不对称合成(R)-(-)邻氯扁桃酸甲酯

目的合成(S)-氯吡咯雷的关键中间体——(R)-(-)邻氯扁桃酸甲酯,并建立了优化的还原条件。方法以邻氯苯乙酮酸甲酯为底物,利用酵母菌DM10的醇脱氢酶及其辅酶合成(R)-(-)邻氯扁桃酸甲酯,并考察了底物质量浓度、初始pH、转化温度和反应时间对不对称还原的影响。结果和结论获得优化的还原条件:接种量体积分数为10%,初始pH值为6.5,底物质量浓度为1 g.L-1,温度为30℃,转化36 h,转化率为98.75%,产率为82.25%,对映体过量值为95.1%。